The South African Health Products Regulatory Authority (SAHPRA) has authorised the use of the CoronaVac Covid-19 vaccine. Manufactured by the Chinese-based Sinovac Life Sciences Co., and imported by Curanto Pharma (Pty) Ltd, the vaccine was given the green light by the South African Health Products Regulatory Authority (SAHPRA). CoronaVac is approved for use in people aged between 18 and 59 years old in the fight against Covid-19. The vaccine is administered as two doses of 0,5ml, given intramuscularly, with the second dose administered between 14 and 28 days after the first dose. SAHPRA said it had granted emergency use of the vaccine based on the safety, quality and efficacy data submitted by Curanto Pharma (Pty) Ltd between March 22 and June 22 this year. The authorisation is subject to a number of conditions, including that the company has to submit the final results of its ongoing clinical studies. The vaccine was given emergency use approval by the World Health Organisation. The vaccine has a provisional shelf life of 24 months and is approved for both the vial and pre-filled syringe presentations, for storage at 2 to 8Â°C and must be protected from light.